$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

$zntl Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000172516024000158 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.61M	$16.76M
YoY Change	-8.43%	7.01%
% of Gross Profit
Research & Development	$36.82M	$48.39M
YoY Change	-21.26%	13.36%
% of Gross Profit
Depreciation & Amortization	$321.0K	$327.0K
YoY Change	-7.76%	-4.94%
% of Gross Profit
Operating Expenses	$51.43M	$65.15M
YoY Change	-17.99%	-37.31%
Operating Profit	-$51.43M	-$65.15M
YoY Change	-17.99%	-37.31%
Interest Expense	$11.25M	-$22.86M
YoY Change	56.01%	-613.66%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$40.19M	-$88.01M
YoY Change	-27.61%	-11.52%
Income Tax	-$27.00K	$266.0K
% Of Pretax Income
Net Earnings	-$40.16M	-$88.28M
YoY Change	-27.68%	-21.55%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.56	-$1.24
Diluted Earnings Per Share	-$0.56	-$1.24
COMMON SHARES
Basic Shares Outstanding	71.11M shares	71.01M shares
Diluted Shares Outstanding	71.11M shares	71.04M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$391.3M	$426.4M
YoY Change	-24.27%	-22.89%
Cash & Equivalents	$41.32M	$36.98M
Short-Term Investments	$349.9M	$389.4M
Other Short-Term Assets	$5.713M	$9.952M
YoY Change	-41.08%	8.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$400.3M	$439.6M
YoY Change	-24.23%	-22.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.016M	$5.337M
YoY Change	-21.54%	-19.74%
Goodwill	$3.736M	$3.736M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.236M	$9.517M
YoY Change	-26.05%	-9.75%
Total Long-Term Assets	$50.39M	$52.06M
YoY Change	-12.29%	-9.48%
TOTAL ASSETS
Total Short-Term Assets	$400.3M	$439.6M
Total Long-Term Assets	$50.39M	$52.06M
Total Assets	$450.7M	$491.7M
YoY Change	-23.06%	-20.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.202M	$20.44M
YoY Change	-42.5%	66.11%
Accrued Expenses	$46.68M	$46.25M
YoY Change	4.53%	17.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$54.88M	$66.69M
YoY Change	-6.86%	28.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$996.0K	$1.089M
YoY Change	-39.05%	-54.17%
Total Long-Term Liabilities	$996.0K	$1.089M
YoY Change	-39.05%	-54.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.88M	$66.69M
Total Long-Term Liabilities	$996.0K	$1.089M
Total Liabilities	$96.33M	$109.1M
YoY Change	-7.21%	11.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.007B	-$966.8M
YoY Change	21.66%	25.21%
Common Stock	$71.00K	$71.00K
YoY Change	1.43%	1.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$354.3M	$382.6M
YoY Change
Total Liabilities & Shareholders Equity	$450.7M	$491.7M
YoY Change	-23.06%	-20.88%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$40.16M	-$88.28M
YoY Change	-27.68%	-21.55%
Depreciation, Depletion And Amortization	$321.0K	$327.0K
YoY Change	-7.76%	-4.94%
Cash From Operating Activities	-$44.04M	-$35.14M
YoY Change	13.92%	-55.67%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$181.0K
YoY Change	-100.0%	-43.26%
Acquisitions
YoY Change
Other Investing Activities	$48.24M	$34.67M
YoY Change	-141.11%	-52.67%
Cash From Investing Activities	$48.24M	$34.49M
YoY Change	-141.08%	-52.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	92.00K	9.000K
YoY Change	-70.61%	-100.0%
NET CHANGE
Cash From Operating Activities	-44.04M	-35.14M
Cash From Investing Activities	48.24M	34.49M
Cash From Financing Activities	92.00K	9.000K
Net Change In Cash	4.290M	-640.0K
YoY Change	-102.75%	-100.28%
FREE CASH FLOW
Cash From Operating Activities	-$44.04M	-$35.14M
Capital Expenditures	$0.00	$181.0K
Free Cash Flow	-$44.04M	-$35.32M
YoY Change	13.66%	-55.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60790000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70969000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70969000	shares
CY2023Q4	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	500000	usd
CY2024Q2	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	12567000	usd
CY2023Q4	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	13640000	usd
CY2024Q2	us-gaap	Interest Receivable InterestReceivable	3279000	usd
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	3337000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	819000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1471000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27075000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25544000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27075000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60038000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60038000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.93
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.93
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71106719	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71106719	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70765554	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70765554	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.93
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71040000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71040000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60790000	shares
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	65000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	221000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	319000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	96035000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	115053000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	235680000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	257000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1314000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	241000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	236994000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8938000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	223489000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30719000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45696000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36976000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	266558000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	2681000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	2627000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39657000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	269185000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	458771000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12711000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-633000	usd
CY2024Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	382581000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	437391000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25544000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2054000	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-240000	usd
	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	79000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	248000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-28000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-78209000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	382581000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385665000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13342000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	218000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235680000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	941000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-37000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-112527000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	523282000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	434024000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27075000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1015000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235680000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	941000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	373000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-80000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175746000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	523282000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable </span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div>
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	361457000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	249000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	110000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	361596000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	452686000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2299000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	104000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	454881000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	22	security
CY2024Q2	us-gaap	Trading Securities Debt TradingSecuritiesDebt	193900000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	21	security
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	1	security
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	100000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	272370000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	267336000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	89226000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	187545000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	361596000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	454881000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	11256000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	27813000	usd
CY2024Q2	us-gaap	Investments Investments	389409000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	400665000	usd
CY2024Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	500000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4755000	usd
CY2023Q4	us-gaap	Investments Investments	454881000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	459636000	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	500000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	778000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	747000	usd
CY2024Q2	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	566000	usd
CY2023Q4	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	691000	usd
CY2024Q2	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	821000	usd
CY2024Q2	zntl	Other Prepaid Expense OtherPrepaidExpense	1237000	usd
CY2023Q4	zntl	Other Prepaid Expense OtherPrepaidExpense	231000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	20067000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	20617000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	6836000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	6818000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13231000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13799000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8973000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8967000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3636000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3148000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5337000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5819000	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	327000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	344000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	651000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	704000	usd
CY2024Q2	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	36145000	usd
CY2023Q4	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	36261000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6471000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14477000	usd
CY2024Q2	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	612000	usd
CY2023Q4	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	1032000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2709000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2623000	usd
CY2024Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	500000	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	500000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	425000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	281000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	479000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1047000	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	47341000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	56221000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1089000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1780000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46252000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54441000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12711000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13342000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25544000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12711000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13342000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1000	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1000	shares
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3330000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6799000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7278000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7451000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7760000	usd
CY2024Q2	zntl	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	31019000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	63637000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19610000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	44027000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2709000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41318000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
	us-gaap	Sublease Income SubleaseIncome	700000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-88277000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-112527000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-78209000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175746000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71040000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71040000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60790000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60790000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70969000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70969000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13891000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11626000	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
zntl-20240630_cal.xml	Edgar Link	unprocessable
0001725160-24-000158-index-headers.html	Edgar Link	pending
0001725160-24-000158-index.html	Edgar Link	pending
0001725160-24-000158.txt	Edgar Link	pending
0001725160-24-000158-xbrl.zip	Edgar Link	pending
epperlym-zentalisxreleas.htm	Edgar Link	pending
epperlym-zentalisxreleas001.jpg	Edgar Link	pending
epperlym-zentalisxreleas002.jpg	Edgar Link	pending
epperlym-zentalisxreleas003.jpg	Edgar Link	pending
epperlym-zentalisxreleas004.jpg	Edgar Link	pending
epperlym-zentalisxreleas005.jpg	Edgar Link	pending
epperlym-zentalisxreleas006.jpg	Edgar Link	pending
epperlym-zentalisxreleas007.jpg	Edgar Link	pending
epperlym-zentalisxreleas008.jpg	Edgar Link	pending
epperlym-zentalisxreleas009.jpg	Edgar Link	pending
epperlym-zentalisxreleas010.jpg	Edgar Link	pending
epperlym-zentalisxreleas011.jpg	Edgar Link	pending
epperlym-zentalisxreleas012.jpg	Edgar Link	pending
epperlym-zentalisxreleas013.jpg	Edgar Link	pending
epperlym-zentalisxreleas014.jpg	Edgar Link	pending
epperlym-zentalisxreleas015.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zentalis10-qq22024ex311.htm	Edgar Link	pending
zentalis10-qq22024ex312.htm	Edgar Link	pending
zentalis10-qq22024ex321.htm	Edgar Link	pending
zentalis10-qq22024ex322.htm	Edgar Link	pending
zntl-20240630.htm	Edgar Link	pending
zntl-20240630.xsd	Edgar Link	pending
zntl-20240630_g1.jpg	Edgar Link	pending
zntl-20240630_def.xml	Edgar Link	unprocessable
zntl-20240630_htm.xml	Edgar Link	completed
zntl-20240630_lab.xml	Edgar Link	unprocessable
zntl-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

2024 Q3 Form 10-Q Financial Statement

#000172516024000158 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL Zentalis Pharmaceuticals, Inc. Stock $zntl

2024 Q3 Form 10-Q Financial Statement

#000172516024000158 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl